Earnings summaries and quarterly performance for Microbot Medical.
Executive leadership at Microbot Medical.
Board of directors at Microbot Medical.
Research analysts who have asked questions during Microbot Medical earnings calls.
Recent press releases and 8-K filings for MBOT.
Microbot Medical to Showcase LIBERTY System at Oncology Conference
MBOT
Product Launch
- Microbot Medical Inc. is attending the Society of Interventional Oncology (SIO) annual meeting from February 4-8, 2026, in Savannah, GA, to support the commercial adoption of its LIBERTY Endovascular Robotic System.
- This conference marks the first commercial exhibition of the LIBERTY System, following its limited market release which commenced in late 2025.
- The company plans for a full market release of the LIBERTY System in April 2026 at the Society of Interventional Radiology (SIR) conference.
- The LIBERTY System is the only FDA cleared, single-use, remotely operated robotic system designed for peripheral endovascular procedures.
1 day ago
Microbot Medical Highlights LIBERTY System at Key Oncology Conference Ahead of Full Market Release
MBOT
Product Launch
- Microbot Medical Inc. is attending the Society of Interventional Oncology (SIO) annual meeting from February 4-8, 2026, to share practical insights from physicians who have used the LIBERTY® Endovascular Robotic System during its limited market release.
- This conference marks the first commercial exhibition of the LIBERTY System, aiming to accelerate commercial awareness and adoption among interventional oncologists.
- The LIBERTY System is the only FDA cleared, single-use, remotely operated robotic system for peripheral endovascular procedures.
- A full market release of the LIBERTY System is planned for April 2026 at the Society of Interventional Radiology (SIR) conference.
1 day ago
Microbot Medical Inc. Announces 2025 Achievements and 2026 Milestones
MBOT
Product Launch
New Projects/Investments
Guidance Update
- Microbot Medical Inc. achieved FDA 510(k) clearance for its LIBERTY® Endovascular Robotic System in 2025 and initiated its Limited Market Release, with Emory University Hospital becoming the first to adopt the system.
- The company plans to commence the Full Market Release (FMR) of the LIBERTY System in Q2 2026.
- In 2025, the LIBERTY system demonstrated 100% robotic navigation success and a 92% reduction in radiation exposure in the ACCESS PVI pivotal trial, targeting a U.S. market of 2.5 million peripheral endovascular procedures annually with plans for international expansion.
- Microbot Medical expanded its IP portfolio to 20 patents granted and 52 patent applications pending in 2025.
Jan 12, 2026, 1:30 PM
Microbot Medical announces 2025 achievements and 2026 commercial milestones
MBOT
Product Launch
Guidance Update
- Microbot Medical Inc. achieved FDA 510(k) clearance for its LIBERTY Endovascular Robotic System and initiated its Limited Market Release in 2025, with Emory University Hospital becoming the first customer.
- The company plans to commence the Full Market Release (FMR) of the LIBERTY System in Q2 2026, coinciding with the Society of Interventional Radiology (SIR) conference.
- Microbot Medical is positioning to commercialize LIBERTY across a targeted U.S. market of 2.5 million peripheral endovascular procedures annually.
- In 2025, the company also bolstered its balance sheet and expanded its IP portfolio with 20 granted patents and 52 pending applications.
Jan 12, 2026, 1:30 PM
Microbot Medical Announces Emory University Hospital Adopts LIBERTY Endovascular Robotic System
MBOT
Product Launch
New Projects/Investments
- Microbot Medical Inc. (MBOT) announced on November 26, 2025, that Emory University Hospital has become the first hospital in the world to adopt its LIBERTY Endovascular Robotic System for patient care.
- The company is also collaborating with Emory to establish an Endovascular Robotics Program in interventional radiology.
- The LIBERTY system is the only FDA cleared, single-use, remotely operated robotic system for peripheral endovascular procedures.
- Microbot Medical recently began a limited market release of the system, with a full market release planned for April 2026 at the Society of Interventional Radiology (SIR) conference.
Nov 26, 2025, 1:30 PM
Microbot Medical Inc. Commences Limited Market Release of LIBERTY® System in U.S.
MBOT
Product Launch
- Microbot Medical Inc. (MBOT) commenced the Limited Market Release (LMR) of its LIBERTY® Endovascular Robotic System in the U.S. on November 5, 2025.
- The LIBERTY® System is the first FDA cleared single-use, remotely operated robotic system for peripheral endovascular procedures.
- The LMR will target selected high procedure volume regions to gather real-world insights, with a Full Market Release (FMR) anticipated in April 2026.
- The company has completed commercial readiness by securing a third-party logistics partner and expanding its commercial leadership team.
Nov 5, 2025, 1:30 PM
Microbot Medical Commences Limited Market Release of LIBERTY® Endovascular Robotic System
MBOT
Product Launch
New Projects/Investments
Hiring
- Microbot Medical Inc. (MBOT) has initiated the Limited Market Release (LMR) of its LIBERTY® Endovascular Robotic System in the U.S., making it commercially available.
- The LIBERTY® System is the first FDA cleared single-use, remotely operated robotic system for peripheral endovascular procedures.
- The LMR will focus on collecting real-world insights, with a Full Market Release anticipated in April 2026 during the Society of Interventional Radiology (SIR) conference.
- The company has completed necessary infrastructure, including hiring a core commercial team and establishing a logistics partnership, following FDA 510(k) clearance in September.
Nov 5, 2025, 1:30 PM
Microbot Medical to Commercially Debut LIBERTY System and Completes Commercial Team Hiring
MBOT
Product Launch
Hiring
New Projects/Investments
- Microbot Medical Inc. (MBOT) will commercially debut its LIBERTY® Endovascular Robotic System at the Symposium on Clinical Interventional Oncology (CIO) annual meeting in Miami, FL, from October 17-19, 2025.
- This event marks the first U.S. commercial exhibition of the LIBERTY® System following its FDA 510(k) clearance in early September 2025.
- The company is on track to commence a limited market release of the LIBERTY® System in Q4 2025.
- To support commercialization, MBOT has completed the hiring and on-boarding of its entire commercial leadership team, including a Regional Sales Director, Sales Training Director, and Marketing Communications Manager.
Oct 16, 2025, 12:30 PM
Microbot Medical Partners with Logistics Provider for LIBERTY System Commercialization
MBOT
Product Launch
New Projects/Investments
- Microbot Medical Inc. (MBOT) has partnered with a U.S. based third-party logistics (3PL) company to support the commercialization of its FDA-cleared LIBERTY® Endovascular Robotic System.
- The company expects to initiate the limited market release of the LIBERTY® System during the fourth quarter of 2025, with a broader launch anticipated in April 2026.
- This partnership aims to ensure effective and efficient inventory management and customer support for the LIBERTY® System.
Oct 14, 2025, 12:42 PM
Microbot Medical Secures U.S. Logistics Partner for LIBERTY® System Commercialization
MBOT
Product Launch
New Projects/Investments
- Microbot Medical Inc. has partnered with a U.S.-based third-party logistics (3PL) company to support the commercialization of its FDA-cleared LIBERTY® Endovascular Robotic System.
- The 3PL company specializes in the medical device industry, providing effective and efficient order processing and inventory management from a strategically located, climate-controlled warehouse.
- The company is on track to initiate a limited market release of the LIBERTY® System during the current fourth quarter of 2025.
- A broader launch of the LIBERTY® System is anticipated in April 2026.
Oct 14, 2025, 12:30 PM
Quarterly earnings call transcripts for Microbot Medical.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more